JP2020523327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523327A5 JP2020523327A5 JP2019568003A JP2019568003A JP2020523327A5 JP 2020523327 A5 JP2020523327 A5 JP 2020523327A5 JP 2019568003 A JP2019568003 A JP 2019568003A JP 2019568003 A JP2019568003 A JP 2019568003A JP 2020523327 A5 JP2020523327 A5 JP 2020523327A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- group
- heart failure
- compound selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 229940125634 FPR2 agonist Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 claims 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517211P | 2017-06-09 | 2017-06-09 | |
| US62/517,211 | 2017-06-09 | ||
| PCT/US2018/036631 WO2018227065A1 (en) | 2017-06-09 | 2018-06-08 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523327A JP2020523327A (ja) | 2020-08-06 |
| JP2020523327A5 true JP2020523327A5 (https=) | 2021-07-26 |
| JP7183193B2 JP7183193B2 (ja) | 2022-12-05 |
Family
ID=62779078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568003A Active JP7183193B2 (ja) | 2017-06-09 | 2018-06-08 | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11186544B2 (https=) |
| EP (1) | EP3634412A1 (https=) |
| JP (1) | JP7183193B2 (https=) |
| KR (1) | KR102623473B1 (https=) |
| CN (1) | CN110996950B (https=) |
| WO (1) | WO2018227065A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3414227B1 (en) | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018227067A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| WO2020257161A1 (en) * | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Biaryl dialkyl phosphine oxide fpr2 agonists |
| EP3789378A1 (en) * | 2019-09-06 | 2021-03-10 | Grünenthal GmbH | Piperidines or piperidones substituted with urea and heteroaryl |
| IL299680A (en) | 2020-07-09 | 2023-03-01 | Bristol Myers Squibb Co | Pyrazolone formyl peptide 2 receptor agonists |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002080853A2 (en) * | 2001-04-09 | 2002-10-17 | Bristol-Myers Squibb Company | Fused heterocyclic inhibitors of factor xa |
| US7678913B2 (en) * | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| SG11201406629VA (en) * | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| ES2752733T3 (es) | 2013-11-28 | 2020-04-06 | Kyorin Seiyaku Kk | Derivados de urea deuterados o marcados isotópicamente o sales farmacológicamente aceptables de los mismos útiles como agonistas de FPRL-1 |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| JP6746613B2 (ja) * | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| CN108348479A (zh) * | 2015-11-24 | 2018-07-31 | 百时美施贵宝公司 | 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病 |
| EP3414227B1 (en) * | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP7155102B2 (ja) * | 2016-07-07 | 2022-10-18 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素 |
| TW201815762A (zh) * | 2016-09-21 | 2018-05-01 | 德商歌林達有限公司 | 經尿素及苯基取代之６員環狀胺或內醯胺 |
| WO2018227067A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) * | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) * | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| WO2020257161A1 (en) * | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Biaryl dialkyl phosphine oxide fpr2 agonists |
-
2018
- 2018-06-08 KR KR1020207000292A patent/KR102623473B1/ko active Active
- 2018-06-08 US US16/619,956 patent/US11186544B2/en active Active
- 2018-06-08 WO PCT/US2018/036631 patent/WO2018227065A1/en not_active Ceased
- 2018-06-08 EP EP18735093.9A patent/EP3634412A1/en not_active Withdrawn
- 2018-06-08 CN CN201880050610.9A patent/CN110996950B/zh not_active Expired - Fee Related
- 2018-06-08 JP JP2019568003A patent/JP7183193B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523327A5 (https=) | ||
| JP2021191784A5 (https=) | ||
| JP2024516371A5 (https=) | ||
| JP2024071370A5 (https=) | ||
| JP2017186358A5 (https=) | ||
| JP2016510326A5 (https=) | ||
| JP2017528503A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2016518337A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| JP2017533930A5 (https=) | ||
| JP2015057436A5 (https=) | ||
| JP2016515561A5 (https=) | ||
| JP2017504611A5 (https=) | ||
| JP2015508749A5 (https=) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2020532547A5 (https=) | ||
| JP2016531126A5 (https=) | ||
| JP2017531619A5 (https=) | ||
| JP2020512337A5 (https=) | ||
| JP2019510027A5 (https=) | ||
| JP2017506666A5 (https=) | ||
| JP2018502824A5 (https=) | ||
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| JP2016529306A5 (https=) |